BioNeutral Group, Inc. (OTCBB: BONU) (OTCQB: BONU), today announced that Quip Laboratories (Quip) is continuing to make progress in its commercialization process of the BioNeutral products for the market segments of laboratory animal research and biomedical research.
Quip Laboratories a leader in sales distribution of cleaning and disinfection solutions to the life science marketplace since 1981 is process of completing the third major element of its 2014 commercialization strategy of the BioNeutral products. First, YGIENE™ 206 and OGIENE™ Odor Eliminator product training was completed during the annual "QUIP University" Sales meeting in March. Second, QUIP has featured YGIENE™ 206 in its recent market awareness campaign of April 4th, April 17thand April 23rd, 2014 and third, YGIENE™ 206 and OGIENE™ OE are scheduled to be introduced at a number of The Life Sciences market trade shows beginning this spring.
A very important element to QUIP's commercialization strategy of the BioNeutral products is the impressive list of Life Sciences trade shows where they will be introducing both YGIENE 206 and OGIENE™ Odor eliminator. The Regional and National Trade Shows will play a major role in establishing both YGIENE™ and OGIENE™ as core products in the impressive portfolio of the highly respected QUIP product offerings. See trade show schedule below:
April 9-11, 2014 - LAMA/ATA Annual Meeting, Scottsdale, AZ
April 17-18, 2014 - 2014 District 8 Meeting, South San Francisco, CA
April 30, 2014 - Mile High Branch Spring 2014 AALAS Meeting, Fort Collins, CO
May 1-2, 2014 - QUAD Symposium, Uncasville, CT
May 13-14, 2014 - The Turn-Key Conference, National Harbor, MD
May 14-16, 2014 - 2014 District 5 AALAS Annual Meeting, Lexington, KY
September 19-20, 2014 - CVMA, Loveland, CA
October 8-12, 2014 - Wild West Vet Conference, Reno, NV
October 19-23, 2014 - 2014 AALAS Nationals, San Antonio, TX
These three elements of QUIP's commercialization strategy will be very important to the success of both YGIENE™ and OGIENE™ to this important market segment for BioNeutral.
"It is great to see QUIP Laboratories aggressively attack the Life Sciences Marketplace with multiple strategies" commented Ray Dunning, Sr. Vice President of Sales for BioNeutral, "with their Sales Team fully trained, the market awareness campaign in full swing and the BioNeutral products being introduced at these well attended trade shows, the Lab Animal Research and Biotech customers will have full access to our exciting new facility hygiene technologies that will become an important weapon to prevent infections."
About Quip Laboratories, Inc.
Based in Wilmington, DE and founded in 1981, Quip Laboratories focuses on providing sanitation solutions to Life Science and Food Processing sectors. Their state-of-the-art manufacturing facility produces proprietary chemicals that have enabled the company to achieve a leadership position in the markets served. Featuring in-house research and development, production, quality control and sales and marketing, Quip provides a "total-systems" approach to providing efficient and eco-gentle environment hygiene. Find Quip at www.quiplabs.com.
About BioNeutral Group, Inc.
Headquartered in Newark, New Jersey, BioNeutral Group, Inc., is a specialty technology-based life-science company that has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral's products, YGIENE™ and OGIENE™, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. For more information on BioNeutral, including a listing of company products, leadership and background please visitwww.bioneutral.com.
Find us on Facebook: http://www.facebook.com/pages/BioNeutral-Group/149109938452393
Follow us on Twitter: http://twitter.com/bioneutralgroup
Forward-Looking Statements: This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA has approved and registered the Company's data and findings specific to Ygiene-206. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene® and are available for sale in the United States.
CONTACT: FOR THE COMPANY:
Mark Lowenthal
CEO
BioNeutral Group, Inc.
+1-973-577-8003
SOURCE: BioNeutral Group, Inc
Associated Documentation:
Link to submission on http://www.eteligis.com
BONU_05-01-2014_MEL_ETL.docx
To unsubscribe from any future mailings, please visit: http://www.eteligis.com/MassMailUnsubscribe.aspx
Copyright eTeligis Inc. 2014. All rights reserved.
0 comments:
Post a Comment